30 April 2024
On 30 April 2024, the Office of the Guangzhou Nansha District Administrative Committee and the Office of the People’s Government of Guangzhou Nansha District issued the “Support Measures for Promoting the High-quality Development of the Biomedicine Industry in Guangzhou Nansha” (“the Measures”). The Measures propose to support qualified Hong Kong and Macau enterprises to conduct medical research on human genetic resources in China, excluding human stem cells and gene diagnosis and treatment. A reward will be provided to qualified foreign-invested enterprises carrying out pilot expansion in the development and application of gene diagnosis and treatment technologies. The reward is calculated at 2% of the enterprise’s actual annual foreign capital investment amount with a maximum of RMB 100 million per year. The Measures is effective from the date of issuance until 30 April 2027.